At a glance
Summary
DaVita closed the week ended 19 June at $207.9, down 0.4% for the week but still up 34.6% over 12 weeks and 51.8% over the past year. The stock sits 2.6% below its 52-week high, 39.1% above its weekly Trend Line and 53.8% above Sharemaestro Fair Value. The signal backdrop remains constructive, with a 15-week active Trend Signal, positive activity pressure and positive Relative Strength. Confirmation is less forceful: volume was 3.6M shares, or 0.9x the 13-week average, while the expectancy state is Undecided at 51.08%.
- DVA ended at $207.9, just 2.6% below its $213.4 52-week high and at 95.1% of its one-year range.
- The weekly Trend Signal is active for a 15-week streak, with price 39.1% above the $149.5 Trend Line.
- The stock trades 53.8% above Sharemaestro Fair Value of $135.2, showing premium demand but also valuation-distance risk.
- Volume confirmation was measured at 3.6M shares, below the 3.9M 13-week average and the 4.3M 52-week average.
- Healthcare breadth remains thin, while Medical Care Facilities shows better activity pressure than the wider sector.
Company analysis
The move in context
Price action pauses near the high after a sharp quarterly advance
DaVita’s weekly close of $207.9 marked only a modest 0.4% decline, but it came after a strong recovery phase: the stock is up 4.7% over four weeks, 34.6% over 12 weeks and 80.5% over 26 weeks. The price remains close to the high-water mark, sitting 2.6% below the $213.4 52-week high and well above the $101.0 low.
The Sharemaestro read is balanced rather than uniformly bullish. The active Trend Signal and 15-week streak keep the weekly regime constructive, but the close is now 39.1% above the Trend Line and 53.8% above Fair Value. That distance supports the view that demand has been strong, while also raising the bar for fresh confirmation.
Healthcare context is mixed, with industry support stronger than sector breadth
The wider US Healthcare group had a soft week, averaging a 1.38% decline, with only 31.0% of names in active weekly trends and 25.0% showing positive Relative Strength. Against that backdrop, DaVita’s small weekly loss was not severe, and its 12-week gain of 34.6% stands well above the sector’s 7.3% average.
The industry comparison is more demanding. US Medical Care Facilities averaged a 0.17% weekly gain, 5.0% over four weeks and 47.9% over 12 weeks, leaving DaVita slightly behind the group’s recent aggregate pace despite its strong absolute move. Industry activity pressure breadth is healthier at 61.7%, but trend breadth of 44.7% and Relative Strength breadth of 42.6% still point to selective participation rather than a broad industry advance.
Market Dynamics are supportive, but not decisive
DaVita’s latest activity-pressure reading is positive at 1.25, though it has slipped 6.8% over four weeks. Relative Strength remains positive at 31.86 and has improved 13.3% over the same period, which helps offset the cooling in activity pressure. The signal panel shows an active trend backdrop, positive activity pressure and positive Relative Strength, but no fresh buy signal.
The expectancy read is Undecided at 51.08%, matching the article’s balanced setup signature and composite score of 66. In practical tape terms, the stock still has evidence of institutional sponsorship, but the latest week did not add a clean acceleration signal.
Volume and risk argue for patience around the next break
Participation was not weak, but it was below the levels that would validate a decisive continuation. Latest volume of 3.6M shares was 0.9x the 13-week average and 0.8x the 52-week average. That contrasts with the higher-participation rallies earlier in the run, including the 31.0% advance on 8.8M shares in early May and the 28.8% jump on 14.8M shares in February.
Risk is no longer trivial after the advance. Thirteen-week volatility is 8.7%, above the 52-week baseline of 6.7%, and the 52-week count is slightly negative at 25 up weeks versus 27 down weeks. The skew remains manageable, with average gains of 4.8% versus average losses of 2.6%, but 10 recent reversal markers in the smart-money tape make exhaustion risk worth monitoring near the high.
What to watch next
The first test is whether DVA can absorb the valuation stretch while holding above the weekly Trend Line, now at $149.5. A continued close near the upper end of the range would keep the trend intact, but a drift lower on rising downside volume would weaken the quality of the signal.
The cleaner confirmation would be a renewed push toward or through the $213.4 high with volume above 1.5x normal participation. Without that, the next few weeks are more about whether activity pressure stabilises, Relative Strength stays positive and the industry’s stronger activity backdrop continues to support the stock.
Peer comparison
How the wider group is behaving
Breadth shows how much of the sector or industry is participating. A company move is more convincing when its peers are improving too.
US Healthcare
100 tracked companiesAbove Trend Line31.0%
Positive Relative Strength25.0%
US Medical Care Facilities
47 tracked companiesAbove Trend Line44.7%
Positive Relative Strength42.6%
Balanced view
What supports the case, and what could weaken it
What is working
- The trend backdrop is active with a 15-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
- Activity pressure is constructive, supporting the smart-money activity read.
What needs caution
- 10 reversal markers appear in the recent smart-money tape.
Research note
This article is for educational market research only and is not financial, investment, trading, tax, or legal advice. Sharemaestro does not make buy, sell, or hold recommendations.
Source and attribution
Source: Sharemaestro. Canonical article: https://sharemaestro.com/news/dva-quarterly-run-fair-value-volume/.
Follow new Sharemaestro research through the RSS feed or JSON feed.